
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934**

For the month of February 2026

Commission File Number: **001-39777**

Nanobiotix S.A.

(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F

On February 25, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[\(c\) Exhibit 99.1. Press release dated February 25, 2026](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nanobiotix S.A.
(Registrant)

Date: February 25, 2026

/s/ Bart Van Rhijn
Bart Van Rhijn
Chief Financial Officer

NANOBIOTIX to Participate in Investor Conferences in March

PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “**Company**”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March:

TD Cowen's Health Care Conference

Date: Wednesday, March 4, 2026

Location: Boston, MA

Time of the fireside chat: 11:10am ET / 5:10pm CET

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

UBS Biotech Summit Miami

Date: Monday, March 9, 2026

Location: Miami Beach, FL

Jefferies Biotech on the Beach Summit

Date: Tuesday, March 10, 2026

Location: Miami Beach, FL

Leerink's Global Healthcare Conference

Date: Wednesday, March 11, 2026

Location: Miami Beach, FL

Time of the fireside chat: 2:20pm EDT / 7:20pm CET

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix

Investor Relations Department

Joanne Choi
VP, Investor Relations (US)
 +1 (713) 609-3150

Communications Department

Brandon Owens
VP, Communications
 +1 (617) 852-4835
contact@nanobiotix.com

Ricky Bhajun
Director, Investor Relations (EU)
 +33 (0) 79 97 29 99

investors@nanobiotix.com

Media Relations

France – **HARDY**
 Caroline Hardy
 +33 06 70 33 49 50

Global – **uncapped**
 Becky Lauer
 +1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com

Attachment

- 2026-02-25 -- NBTX -- Presenting @ March Conferences --
FINAL (<https://ml.globenewswire.com/Resource/Download/897f5600-4652-4f63-a9e2-9690182f484e>)